DNTH
Dianthus Therapeutics, Inc.Healthcare · $5.0B market cap
Verdict
We can't put a fair value on DNTH right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow DNTH
Track it on your watchlist and see the full analysis. Free.
Create a free accountSuperinvestors
1 of the investors we track holds DNTH. In Q2 2026, 1 added. Who we track
Moves in Q2 2026
Added: Polen Capital Management
Insider activity
Since Sep 1, 2026: no open-market purchases, 3 sales worth $2.5M and 3 other filings (stock awards, tax withholding and similar). Why purchases matter
Sales
Randhawa Simrat
EVP, Head of R&D · 2026-09-01
Sold
$1.4M
Randhawa Simrat
EVP, Head of R&D · 2026-09-01
Sold
$767K
Randhawa Simrat
EVP, Head of R&D · 2026-09-01
Sold
$273K
Other filings
About Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works